TXMD TherapeuticsMD Inc
Price (delayed)
$1
Market cap
$11.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.19
Enterprise value
$12.06M
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women
Highlights
The company's EPS has surged by 81% YoY and by 30% QoQ
The net income has soared by 79% YoY and by 34% from the previous quarter
The equity has contracted by 7% YoY
Key stats
What are the main financial stats of TXMD
Market
Valuations
Earnings
Shares outstanding
11.57M
Market cap
$11.57M
Enterprise value
$12.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
6.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.85
Revenue
$1.76M
Gross profit
$1.76M
Operating income
-$4.76M
Net income
-$2.18M
EBIT
-$2.21M
EBITDA
-$1.7M
Free cash flow
$732,000
Per share
Balance sheet
Liquidity
EPS
-$0.19
EPS diluted
-$0.19
Free cash flow per share
$0.06
Book value per share
$2.37
Revenue per share
$0.15
TBVPS
$2.99
Total assets
$38.82M
Total liabilities
$11.45M
Debt
$5.54M
Equity
$27.37M
Working capital
$7.09M
Debt to equity
0.2
Current ratio
2.37
Quick ratio
1.67
Net debt/EBITDA
-0.28
Margins
Efficiency
Dividend
EBITDA margin
-96.7%
Gross margin
100%
Net margin
-123.9%
Operating margin
-270.3%
Return on assets
-5.4%
Return on equity
-7.9%
Return on invested capital
-7.3%
Return on capital employed
-6.6%
Return on sales
-125.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TXMD stock price
How has the TherapeuticsMD stock price performed over time
Intraday
2.04%
1 week
-0.99%
1 month
7.53%
1 year
-55.56%
YTD
16.28%
QTD
8.11%
Financial performance
How have TherapeuticsMD's revenue and profit performed over time
Revenue
$1.76M
Gross profit
$1.76M
Operating income
-$4.76M
Net income
-$2.18M
Gross margin
100%
Net margin
-123.9%
TXMD's net margin has surged by 84% year-on-year and by 40% since the previous quarter
The net income has soared by 79% YoY and by 34% from the previous quarter
TXMD's operating margin has surged by 59% year-on-year and by 29% since the previous quarter
TherapeuticsMD's operating income has increased by 44% YoY and by 21% QoQ
Growth
What is TherapeuticsMD's growth rate over time
Valuation
What is TherapeuticsMD stock price valuation
P/E
N/A
P/B
0.42
P/S
6.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.85
The company's EPS has surged by 81% YoY and by 30% QoQ
The stock's price to book (P/B) is 41% less than its last 4 quarters average of 0.7
The equity has contracted by 7% YoY
TXMD's price to sales (P/S) is 56% lower than its last 4 quarters average of 14.6 and 38% lower than its 5-year quarterly average of 10.4
TXMD's revenue is up by 35% year-on-year and by 10% since the previous quarter
Efficiency
How efficient is TherapeuticsMD business performance
The company's return on sales has surged by 84% YoY and by 42% QoQ
The ROIC has soared by 81% YoY and by 34% from the previous quarter
TherapeuticsMD's ROE has soared by 77% YoY and by 33% from the previous quarter
TXMD's return on assets has surged by 73% year-on-year and by 33% since the previous quarter
Dividends
What is TXMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TXMD.
Financial health
How did TherapeuticsMD financials performed over time
TXMD's quick ratio has surged by 55% year-on-year and by 19% since the previous quarter
TherapeuticsMD's current ratio has increased by 38% YoY and by 17% from the previous quarter
TXMD's debt is 80% smaller than its equity
TXMD's debt is down by 15% year-on-year and by 4.1% since the previous quarter
TXMD's debt to equity is down by 9% year-on-year and by 4.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.